Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide

Pediatr Blood Cancer. 2009 Dec;53(6):1111-3. doi: 10.1002/pbc.22200.

Abstract

Langerhans cell histiocytosis (LCH) has previously been reported in association with other malignancies. The pathogenesis of LCH and its relationship to other malignancies is poorly understood. We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Bone Neoplasms / etiology
  • Child
  • Fenretinide / therapeutic use*
  • Histiocytosis, Langerhans-Cell / diagnosis
  • Histiocytosis, Langerhans-Cell / etiology*
  • Histiocytosis, Langerhans-Cell / pathology
  • Humans
  • Male
  • Neuroblastoma / complications*
  • Neuroblastoma / drug therapy

Substances

  • Fenretinide